A Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of VX-407 in Healthy Participants

Phase 1 Completed 159 enrolled Vertex Pharmaceuticals Incorporated

RandomizedSequentialQuadruple-blindTreatment

The purpose of the study is to evaluate the safety, tolerability, and pharmacokinetic parameters of VX-407 in healthy participants.

Evaluation	Drug	Modality	Dose	Route
Subject	Midazolam	Small molecule	—	Oral
Subject	VX-407	Unknown	—	Oral